144 related articles for article (PubMed ID: 25979262)
21. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
[TBL] [Abstract][Full Text] [Related]
22. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells.
Matsunaga T; Maruyama M; Matsubara T; Nagata K; Yamazoe Y; Ohmori S
Drug Metab Pharmacokinet; 2012; 27(6):653-7. PubMed ID: 22673009
[TBL] [Abstract][Full Text] [Related]
24. Differential effect of Shenmai injection, a herbal preparation, on the cytochrome P450 3A-mediated 1'-hydroxylation and 4-hydroxylation of midazolam.
Xia C; Sun J; Wang G; Shang L; Zhang X; Zhang R; Wang X; Hao H; Xie L
Chem Biol Interact; 2009 Aug; 180(3):440-8. PubMed ID: 19557931
[TBL] [Abstract][Full Text] [Related]
25. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
26. Identification of CYP3A7 for glyburide metabolism in human fetal livers.
Shuster DL; Risler LJ; Prasad B; Calamia JC; Voellinger JL; Kelly EJ; Unadkat JD; Hebert MF; Shen DD; Thummel KE; Mao Q
Biochem Pharmacol; 2014 Dec; 92(4):690-700. PubMed ID: 25450675
[TBL] [Abstract][Full Text] [Related]
27. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
28. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
[TBL] [Abstract][Full Text] [Related]
30. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers.
Vyhlidal CA; Bi C; Ye SQ; Leeder JS
Drug Metab Dispos; 2016 Jul; 44(7):1020-6. PubMed ID: 26772622
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
33. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
Yang J; Atkins WM; Isoherranen N; Paine MF; Thummel KE
Clin Pharmacol Ther; 2012 Mar; 91(3):442-9. PubMed ID: 22048224
[TBL] [Abstract][Full Text] [Related]
34. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
35. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
37. Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.
Guo Y; Lucksiri A; Dickinson GL; Vuppalanchi RK; Hilligoss JK; Hall SD
Clin Pharmacol Ther; 2020 Jan; 107(1):246-256. PubMed ID: 31356678
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
[TBL] [Abstract][Full Text] [Related]
39. Bimodal distribution of renal cytochrome P450 3A activity in humans.
Haehner BD; Gorski JC; Vandenbranden M; Wrighton SA; Janardan SK; Watkins PB; Hall SD
Mol Pharmacol; 1996 Jul; 50(1):52-9. PubMed ID: 8700118
[TBL] [Abstract][Full Text] [Related]
40. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
